Suberanilohydroxamic Acid. Aton Pharma.

Author(s): Johnstone RW

Affiliation(s): Gene Regulation Laboratory, Cancer Immunology Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3200, Australia. r.johnstone@pmci.unimelb.edu.au

Publication date & source: 2004-07, IDrugs., 7(7):674-82.

Publication type: Review

Aton Pharma Inc, under license from the Memorial Sloan-Kettering Cancer Center, is developing suberanilohydroxamic acid (SAHA), a cytodifferentiating agent and histone deacetylase inhibitor, as a potential cancer chemopreventive.